Inactivation des pathogènes des produits sanguins labiles: entre enjeux financiers et conséquences possibles à long terme [Pathogen reduction of blood components: from financial issues to possible long-term consequences].

Details

Serval ID
serval:BIB_540097E98FF2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Inactivation des pathogènes des produits sanguins labiles: entre enjeux financiers et conséquences possibles à long terme [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
Journal
Transfusion Clinique et Biologique
Author(s)
Canellini G., Wasserfallen J.B., Tissot J.D.
ISSN
1953-8022 (Electronic)
ISSN-L
1246-7820
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
18
Number
4
Pages
493-497
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
Pathogen inactivation of blood products represents a global and major paradigm shift in transfusion medicine. In the next near future, it is likely that most blood products will be inactivated by various physicochemical approaches. The concept of blood safety will be challenged as well as transfusion medicine practice, notably for donor selection or biological qualification. In this context, it seems mandatory to develop analytical economic approaches by assessing costs-benefits ratio of blood transfusion as well as to set up cohorts of patients based on hemovigilance networks allowing rigorous scientific analysis of the benefits and the risks of blood transfusion at short- and long-term.
Keywords
Blood Component Transfusion/adverse effects, Blood-Borne Pathogens, Humans, Infection Control/economics, Infection Control/methods
Pubmed
Web of science
Create date
08/09/2011 20:23
Last modification date
20/08/2019 14:09
Usage data